Enhancing Pharmacovigilance in Côte d'Ivoire: Impact of GSK’s Training and Mentoring Pilot Project in the Abidjan Region

Yolanda Guerra Mendoza, Viviane Jusot (), Félix Adou, Martin Ota, Diego Mpia Elenge, Tasim Begum, Nkululeko Mdladla, Olga Menang, Jean Claude Yavo and Mamadou Kamagaté
Additional contact information
Yolanda Guerra Mendoza: GSK
Viviane Jusot: GSK
Félix Adou: Autorité Ivoirienne de Régulation Pharmaceutique (AIRP)
Martin Ota: GSK
Diego Mpia Elenge: GSK
Tasim Begum: GSK Consumer Healthcare
Nkululeko Mdladla: ViiV Healthcare
Olga Menang: PATH
Jean Claude Yavo: Autorité Ivoirienne de Régulation Pharmaceutique (AIRP)
Mamadou Kamagaté: Service de pharmacologie clinique, UFR-sciences médicales Bouaké, université Alassane-Ouattara

Drug Safety, 2024, vol. 47, issue 2, No 5, 147-159

Abstract: Abstract Introduction Pharmacovigilance (PV) in sub-Saharan Africa relies on passive surveillance but underreporting of adverse events (AEs) by health care professionals (HCPs) is a major challenge. A PV enhancement project was implemented to address this in Côte d’Ivoire. Objective To improve safety surveillance of medicines through PV training and mentoring of HCPs in selected health care facilities (HCFs). Methods This collaborative project between national PV stakeholders, GSK, and PATH was implemented from September 2018 to February 2020 in Abidjan region, Côte d’Ivoire. Trained PV focal points provided training and regular mentoring of HCPs. Key performance indicator (KPI) categories for AE reporting were the volume of AE reports, efficiency of report transmission and data entry, quality of reports, and quality of the central (Vigilance Unit) response to AE reports. Results Overall, 1427 HCPs at 91 HCFs were trained. In the 8 months before implementation, 33 AE reports were received versus 85 after 3 months and 361 after 18 months of implementation (71 [83.5%] and 278 [77.0%], respectively, from Abidjan). The KPIs with the highest proportions were: AE reports received centrally (100%), complete AE reports (69.0%), AE reports entered into the local PV database within 48 h (99.6%), and AE reports entered into the global database, VigiBase (86.7%). Report notification within 72 h, causality assessment, and serious AE reporting had proportions below 20%; feedback to reporters was provided for only 0.4% of reports. Conclusion Regular PV trainings and mentoring improved AE reporting in Côte d’Ivoire but further enhancement is required to improve passive safety surveillance.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-023-01368-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:47:y:2024:i:2:d:10.1007_s40264-023-01368-3

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-023-01368-3

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().